整理 | GLP1减重宝典内容团队在全球减重药物竞争逐步从“体重数字”走向“并发症获益”的背景下,中国创新药正在加速进入更具医学价值的细分战场。2月2日,联邦制药 全资附属公司联邦生物科技(珠海横琴)有限公司宣布,其自主研发的1类新药UBT251注射液,针对合并肥胖的中重度阻塞性睡眠呼吸暂停(OSA)新适应症,已正式获得 国家药品监督管理局 批准开展临床试验。这一进展不仅意味着UBT251的适应症...
Source Link整理 | GLP1减重宝典内容团队在全球减重药物竞争逐步从“体重数字”走向“并发症获益”的背景下,中国创新药正在加速进入更具医学价值的细分战场。2月2日,联邦制药 全资附属公司联邦生物科技(珠海横琴)有限公司宣布,其自主研发的1类新药UBT251注射液,针对合并肥胖的中重度阻塞性睡眠呼吸暂停(OSA)新适应症,已正式获得 国家药品监督管理局 批准开展临床试验。这一进展不仅意味着UBT251的适应症...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.